Divergent trajectories of antiviral memory after SARS-CoV-2 infection

19Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The trajectories of acquired immunity to severe acute respiratory syndrome coronavirus 2 infection are not fully understood. We present a detailed longitudinal cohort study of UK healthcare workers prior to vaccination, presenting April-June 2020 with asymptomatic or symptomatic infection. Here we show a highly variable range of responses, some of which (T cell interferon-gamma ELISpot, N-specific antibody) wane over time, while others (spike-specific antibody, B cell memory ELISpot) are stable. We use integrative analysis and a machine-learning approach (SIMON - Sequential Iterative Modeling OverNight) to explore this heterogeneity. We identify a subgroup of participants with higher antibody responses and interferon-gamma ELISpot T cell responses, and a robust trajectory for longer term immunity associates with higher levels of neutralising antibodies against the infecting (Victoria) strain and also against variants B.1.1.7 (alpha) and B.1.351 (beta). These variable trajectories following early priming may define subsequent protection from severe disease from novel variants.

Cite

CITATION STYLE

APA

Tomic, A., Skelly, D. T., Ogbe, A., O’Connor, D., Pace, M., Adland, E., … Dunachie, S. J. (2022). Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-28898-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free